Access cutting-edge heart failure treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Access heart failure specialists in San Francisco at no cost
This study follows strict safety protocols and ethical guidelines
All study-related heart failure treatment provided free
It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.
Sponsor: Sardocor Corp.
Check if you qualify for this heart failure clinical trial in San Francisco, CA
If you're searching for heart failure treatment options in San Francisco, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart failure specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.